TNSN99013A1 - Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
TNSN99013A1
TNSN99013A1 TNTNSN99013A TNSN99013A TNSN99013A1 TN SN99013 A1 TNSN99013 A1 TN SN99013A1 TN TNSN99013 A TNTNSN99013 A TN TNSN99013A TN SN99013 A TNSN99013 A TN SN99013A TN SN99013 A1 TNSN99013 A1 TN SN99013A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
acid derivatives
dihydroxyhexanoic acid
Prior art date
Application number
TNTNSN99013A
Other languages
English (en)
French (fr)
Inventor
Charles Kath John
Frank Brown Matthew
Stanley Poss Christopher
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN99013A1 publication Critical patent/TNSN99013A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
TNTNSN99013A 1998-02-05 1999-02-03 Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant TNSN99013A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05

Publications (1)

Publication Number Publication Date
TNSN99013A1 true TNSN99013A1 (fr) 2005-11-10

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99013A TNSN99013A1 (fr) 1998-02-05 1999-02-03 Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (36)

Country Link
EP (1) EP1051405B1 (enExample)
JP (1) JP3693916B2 (enExample)
KR (1) KR100385529B1 (enExample)
CN (1) CN1177834C (enExample)
AP (1) AP992A (enExample)
AR (1) AR016175A1 (enExample)
AT (1) ATE337307T1 (enExample)
AU (1) AU752407B2 (enExample)
BG (1) BG104726A (enExample)
BR (1) BR9907655A (enExample)
CA (1) CA2320388C (enExample)
DE (1) DE69932920T2 (enExample)
DZ (1) DZ2717A1 (enExample)
EA (1) EA003137B1 (enExample)
ES (1) ES2268847T3 (enExample)
GT (1) GT199900011A (enExample)
HR (1) HRP20000529B1 (enExample)
HU (1) HUP0100832A3 (enExample)
IL (1) IL137330A0 (enExample)
IS (1) IS5562A (enExample)
MA (1) MA26603A1 (enExample)
MY (1) MY133125A (enExample)
NO (1) NO20003965D0 (enExample)
NZ (1) NZ505724A (enExample)
OA (1) OA11448A (enExample)
PA (1) PA8467301A1 (enExample)
PE (1) PE20000243A1 (enExample)
PL (1) PL342817A1 (enExample)
SK (1) SK11262000A3 (enExample)
TN (1) TNSN99013A1 (enExample)
TR (1) TR200002248T2 (enExample)
TW (1) TW470744B (enExample)
UA (1) UA57824C2 (enExample)
WO (1) WO1999040061A2 (enExample)
YU (1) YU47100A (enExample)
ZA (1) ZA99873B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044365A1 (en) * 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Methods for preventing graft rejection and ischemia-reperfusion injury
CA2376275A1 (en) * 1999-08-20 2001-03-01 Michael John Ricks Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
BR0108002A (pt) * 2000-02-04 2002-10-29 Pfizer Prod Inc Derivados de amidas heterocìclicas
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
KR100759635B1 (ko) 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
RU2004133530A (ru) * 2002-05-14 2005-06-10 Пфайзер Продактс Инк. (Us) Производные дигидроксигексановой кислоты, их промежуточные соединения и способы получения
BR0309932A (pt) * 2002-05-14 2005-02-09 Pfizer Prod Inc Métodos para a fabricação de derivados de diidro-furan-2-ona
CN1681479A (zh) 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
CA2494776A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Crystal forms of quinoxaline-2-carboxylic acid ¬4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl|-amide
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
DE69527405T2 (de) * 1994-10-19 2003-03-13 Novartis Ag, Basel Antivirale Ether von Aspartat-Protease-Substrat-Isosteren
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
DE69932920T2 (de) 2007-02-08
YU47100A (sh) 2002-11-15
HRP20000529A2 (en) 2001-08-31
WO1999040061A3 (en) 1999-10-21
HUP0100832A3 (en) 2002-03-28
NZ505724A (en) 2003-02-28
BG104726A (en) 2001-04-30
TW470744B (en) 2002-01-01
NO20003965L (enExample) 2000-10-03
TR200002248T2 (tr) 2000-12-21
EP1051405A2 (en) 2000-11-15
DE69932920D1 (de) 2006-10-05
KR20010040684A (ko) 2001-05-15
EP1051405B1 (en) 2006-08-23
AP992A (en) 2001-08-06
IS5562A (is) 2000-07-14
DZ2717A1 (fr) 2003-09-01
HUP0100832A2 (hu) 2002-02-28
ES2268847T3 (es) 2007-03-16
CA2320388A1 (en) 1999-08-12
NO20003965D0 (no) 2000-08-04
HK1034969A1 (en) 2001-11-09
EA003137B1 (ru) 2003-02-27
JP3693916B2 (ja) 2005-09-14
GT199900011A (es) 2000-07-20
PL342817A1 (en) 2001-07-02
HRP20000529B1 (en) 2004-12-31
WO1999040061A2 (en) 1999-08-12
UA57824C2 (uk) 2003-07-15
AR016175A1 (es) 2001-06-20
ATE337307T1 (de) 2006-09-15
CN1177834C (zh) 2004-12-01
MY133125A (en) 2007-10-31
PE20000243A1 (es) 2000-04-07
AP9901457A0 (en) 1999-03-31
AU752407B2 (en) 2002-09-19
SK11262000A3 (sk) 2001-01-18
BR9907655A (pt) 2000-10-24
ZA99873B (en) 2000-08-04
CN1290255A (zh) 2001-04-04
EA200000741A1 (ru) 2001-02-26
PA8467301A1 (es) 2000-05-24
MA26603A1 (fr) 2004-12-20
JP2002502839A (ja) 2002-01-29
AU1778999A (en) 1999-08-23
CA2320388C (en) 2005-05-03
IL137330A0 (en) 2001-07-24
OA11448A (en) 2003-11-18
KR100385529B1 (ko) 2003-05-27

Similar Documents

Publication Publication Date Title
TNSN98036A1 (fr) Derives d'acide hexanoique nouveaux
TNSN99156A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98238A1 (fr) Macrolides nouveaux
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN01091A1 (fr) Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97145A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.